Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:
Arrowhead Pharmaceuticals and partner Takeda Pharmaceuticals are nearing the completion of a mid-stage, placebo-controlled clinical trial of an RNA-based drug called fazirsiran in patients with alpha-1 antitrypsin deficiency, or AATD, an inherited disease that causes severe liver and lung damage. Participants in the study have undergone liver biopsies at baseline and one year to determine if fazirsiran improves disease symptoms, including liver fibrosis.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
